GENE ONLINE|News &
Opinion
Blog

Regulatory
Trials & Approvals Cancer
Merck Breaks Off Keytruda Combo Trial with AstraZeneca, Begins Another with Imugene
2022-03-16
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
2022-03-15
Trials & Approvals Antibiotic Resistance
Venatorx Gears Up for FDA Approval after Antibiotic Clears Phase 3
2022-03-11
Trials & Approvals FDA
Pfizer’s RSV Vaccine Bags FDA Breakthrough Therapy Status
2022-03-07
Trials & Approvals Cell Therapy
J&J, Legend’s Cell Therapy Gets FDA Nod
2022-03-01
Trials & Approvals Kidney Disease
EU Greenlight for Bayer’s Kidney Disease Drug, Kicking off Market Rivalry Against Established SGLT-2 Inhibitors 
2022-03-01
COVID-19 COVID-19
Plant-Based COVID-19 Vaccine Approved in Canada
2022-03-01
Regulatory Gene Therapy
Homology Medicines Joins Biomarin in Gene Therapy Clinical Hold
2022-02-22
Trials & Approvals EU
EMA Accepts Application for AstraZeneca’s Anti-RSV Antibody Nirsevimab.
2022-02-21
China Cholesterol
Innovent’s PCSK-9 Antibody Meets Primary Endpoints in Two Phase 3 Studies
2022-02-18
Trials & Approvals Anemia
European Commission Approves Global Blood Therapeutics’ Oxbryta for Sickle Cell Disease
2022-02-17
Technology HUMIRA
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
2022-02-16
China Gene Editing
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
COVID-19 COVID-19
FDA Gives Emergency Approval for Lilly’s Anti-Omicron Antibody Treatment
2022-02-14
China Autoimmune
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
1 … 23 24 25 26 27 … 53
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top